Literature DB >> 26643921

Inhalable Spray-Freeze-Dried Powder with L-Leucine that Delivers Particles Independent of Inspiratory Flow Pattern and Inhalation Device.

Hiroko Otake1, Tomoyuki Okuda1, Daiki Hira1,2, Haruyoshi Kojima1, Yasuhiro Shimada3, Hirozazu Okamoto4.   

Abstract

PURPOSE: The purpose of this study was to develop inhalable particles that can reach deep into the lungs efficiently independent of inhalation patterns of patients and inhalation devices. We prepared porous particles including L-leucine (Leu), a dispersive agent, by a spray-freeze-drying (SFD) method and examined the influence of inspiratory flow patterns and inhalation devices with various inhalation resistances.
METHODS: Four types of SFD powder with different Leu contents (0-10%) were prepared. Scanning electron microscopy and laser diffraction were used to measure the morphology and size distribution of the powders. In-vitro inhalation characteristics were determined using a twin-stage liquid impinger equipped with an inspiratory flow pattern simulator. The effects of Leu on the adhesion force and electrostatic property of the particles were evaluated.
RESULTS: The inhalation performance of the powders was improved by the addition of Leu. The powders with Leu showed a high inhalation performance regardless of inspiratory flow patterns and devices. The addition of Leu decreased the adhesion force and increased the surface potential of the powders.
CONCLUSIONS: The SFD particles with Leu showed high inhalation performance regardless of the inhalation patterns and devices, which was attributed to the decreased adhesion force between particles and increased dispersibility.

Entities:  

Keywords:  L-leucine (Leu); dry powder inhaler (DPI); inhalation device; inspiratory flow pattern; spray-freeze-drying (SFD)

Mesh:

Substances:

Year:  2015        PMID: 26643921     DOI: 10.1007/s11095-015-1838-4

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  35 in total

1.  The use of amino acids to enhance the aerosolisation of spray-dried powders for pulmonary gene therapy.

Authors:  H-Y Li; P C Seville; I J Williamson; J C Birchall
Journal:  J Gene Med       Date:  2005-03       Impact factor: 4.565

2.  Adhesion forces in interactive mixtures for dry powder inhalers--evaluation of a new measuring method.

Authors:  Maike Lohrmann; Michael Kappl; Hans-Juergen Butt; Nora Anne Urbanetz; Bernhard Christian Lippold
Journal:  Eur J Pharm Biopharm       Date:  2007-02-22       Impact factor: 5.571

Review 3.  Recent advances in pulmonary drug delivery using large, porous inhaled particles.

Authors:  D A Edwards; A Ben-Jebria; R Langer
Journal:  J Appl Physiol (1985)       Date:  1998-08

4.  Primary microparticles and agglomerates of morphine for nasal insufflation.

Authors:  Paola Russo; Cecilia Sacchetti; Irene Pasquali; Ruggero Bettini; Gina Massimo; Paolo Colombo; Alessandra Rossi
Journal:  J Pharm Sci       Date:  2006-12       Impact factor: 3.534

5.  Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease.

Authors:  Handoko Adi; Paul M Young; Hak-Kim Chan; Helen Agus; Daniela Traini
Journal:  Eur J Pharm Sci       Date:  2010-04-03       Impact factor: 4.384

6.  Engineering gas-foamed large porous particles for efficient local delivery of macromolecules to the lung.

Authors:  Francesca Ungaro; Concetta Giovino; Ciro Coletta; Raffaella Sorrentino; Agnese Miro; Fabiana Quaglia
Journal:  Eur J Pharm Sci       Date:  2010-05-25       Impact factor: 4.384

7.  Pure insulin nanoparticle agglomerates for pulmonary delivery.

Authors:  Mark M Bailey; Eric M Gorman; Eric J Munson; Cory Berkland
Journal:  Langmuir       Date:  2008-12-02       Impact factor: 3.882

Review 8.  Inhalation therapy: technological milestones in asthma treatment.

Authors:  Richard Dalby; Julie Suman
Journal:  Adv Drug Deliv Rev       Date:  2003-07-18       Impact factor: 15.470

9.  Inspiratory flows through dry powder inhaler in chronic obstructive pulmonary disease: age and gender rather than severity matters.

Authors:  L Pekka Malmberg; Paula Rytilä; Pertti Happonen; Tari Haahtela
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2010-08-09

10.  Insulin-loaded PLGA/cyclodextrin large porous particles with improved aerosolization properties: in vivo deposition and hypoglycaemic activity after delivery to rat lungs.

Authors:  Francesca Ungaro; Roberta d'Emmanuele di Villa Bianca; Concetta Giovino; Agnese Miro; Raffaella Sorrentino; Fabiana Quaglia; Maria Immacolata La Rotonda
Journal:  J Control Release       Date:  2008-12-25       Impact factor: 9.776

View more
  4 in total

Review 1.  Influence of physical properties of carrier on the performance of dry powder inhalers.

Authors:  Tingting Peng; Shiqi Lin; Boyi Niu; Xinyi Wang; Ying Huang; Xuejuan Zhang; Ge Li; Xin Pan; Chuanbin Wu
Journal:  Acta Pharm Sin B       Date:  2016-05-04       Impact factor: 11.413

2.  Moisture-Resistant Co-Spray-Dried Netilmicin with l-Leucine as Dry Powder Inhalation for the Treatment of Respiratory Infections.

Authors:  Yingtong Cui; Xuejuan Zhang; Wen Wang; Zhengwei Huang; Ziyu Zhao; Guanlin Wang; Shihao Cai; Hui Jing; Ying Huang; Xin Pan; Chuanbin Wu
Journal:  Pharmaceutics       Date:  2018-12-01       Impact factor: 6.321

3.  Systemic Delivery of hGhrelin Derivative by Lyophilizate for Dry Powder Inhalation System in Monkeys.

Authors:  Kahori Miyamoto; Yuko Ishibashi; Tomomi Akita; Chikamasa Yamashita
Journal:  Pharmaceutics       Date:  2021-02-07       Impact factor: 6.321

4.  Dry Powder Inhalers for Proteins Using Cryo-Milled Electrospun Polyvinyl Alcohol Nanofiber Mats.

Authors:  Takaaki Ito; Eriko Yamazoe; Kohei Tahara
Journal:  Molecules       Date:  2022-08-12       Impact factor: 4.927

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.